SCHEMBL5128346

SCHEMBL5128346

Cc1c2c(=O)n(CCCN)c3cc4c(cc3c2nn1Cc1ccccc1)CCCC4

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 7/20 0.41
KCNH2 Q12809 1/20 0.41
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
ADORA1 P30542 4/20 0.34
PDE5A O76074 3/20 0.34
PDE6D O43924 1/20 0.34
PDE6A P16499 1/20 0.34
PDE6G P18545 1/20 0.34
ADORA2B P29275 1/20 0.34
PDE6B P35913 1/20 0.34
PDE6C P51160 1/20 0.34
PDE6H Q13956 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.33
AADAT Q8N5Z0 1/20 0.33
PDE4A P27815 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5128358 0.86 CNR2 (0.36) CHEK1MEN1KMT2AKDM4EALDH1A1
SCHEMBL14192082 0.83 PDE4A (0.35) CHEK1KCNH2MEN1KMT2AKDM4E
SCHEMBL5129516 0.82 CNR2 (0.41) MEN1KMT2ATDP1PTGDR2
SCHEMBL14192084 0.77 PRMT5 (0.34) CHEK1MEN1KMT2AKDM4EALDH1A1
SCHEMBL14192083 0.76 GAA (0.33) PDE5APDE4APDE4BPDE4CPDE4D
SCHEMBL5132330 0.74 CHEK1 (0.68) CHEK1KCNH2
SCHEMBL4018879 0.73 CHEK1 (0.51) CHEK1MEN1KMT2AKDM4EALDH1A1
SCHEMBL5130032 0.72 CHEK1 (0.68) CHEK1KCNH2
SCHEMBL5128848 0.69 CHEK1 (0.48) CHEK1KCNH2PDE4APDE4BPDE4C
SCHEMBL5130088 0.69 CHEK1 (0.47) CHEK1KCNH2MEN1KMT2APDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080114016-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2008-05-15 US disclosed
US-20080114016-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2008-05-15 US disclosed
US-20080114016-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2008-05-15 US disclosed
EP-1835918-A2 INHIBITORS OF CHECKPOINT KINASES Merck & Co., Inc. (US) 2007-09-26 EP disclosed
WO-2006074281-A2 INHIBITORS OF CHECKPOINT KINASES MERCK & CO., INC. (US) 2006-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114016-A1 Inhibitors of Checkpoint Kinases CHEK1, CHEK2, BUB1B CHEK1 1/4885KCNH2 3426/4885MEN1 842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.